GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Prescient Therapeutics Ltd (FRA:UDD) » Definitions » Short Percentage of Float

Prescient Therapeutics (FRA:UDD) Short Percentage of Float


View and export this data going back to 2006. Start your Free Trial

What is Prescient Therapeutics Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Prescient Therapeutics's Short Percentage of Float

For the Biotechnology subindustry, Prescient Therapeutics's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Prescient Therapeutics's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Prescient Therapeutics's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Prescient Therapeutics's Short Percentage of Float falls into.


Prescient Therapeutics (FRA:UDD) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Prescient Therapeutics Ltd (FRA:UDD) » Definitions » Short Percentage of Float
Comparable Companies
ASX:EZZ ASX:CYP ASX:LTP ASX:ATH ASX:BIT ASX:ADO ASX:SPL ASX:CHM ASX:IMC ASX:RAD OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB XBRU:ARGX BNTX
Traded in Other Exchanges
PTX:Australia
Address
Level 4, 100 Albert Road, South Melbourne, Melbourne, VIC, AUS, 3205
Website
https://www.ptxtherapeutics.com
Prescient Therapeutics Ltd is a clinical-stage oncology company. The company develops novel compounds for the treatment of a range of cancers in Australia. Its product in the pipeline includes OmniCAR; PTX-100 and PTX-200. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product.

Prescient Therapeutics (FRA:UDD) Headlines

No Headlines